8 / 9
E u r o p e a n C o n g r e s s o n
Advanced Chemistry
Advanced Chemistry 2018
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
Page 31
Journal of Organic & Inorganic Chemistry
ISSN: 2472-1123
C
hronic pain affects 1.5 billion people worldwide, causing a great deal
of discomfort among patients and an enormous economic and societal
burden. Inadequate pain control, undesirable side-effects associated with
current analgesics as well the recent opioid crisis have revived interest in
analgesic drug development. The challenge is to develop original analgesics
with novel modes of action to address the unmet needs of patients. Pichon
recently reported that disrupting the interaction between the PDZ-containing
protein PSD-95, and the endogenous ligand 5-HT2A receptor, reduced
hyperalgesia suggesting inhibition of this PDZ protein could result in analgesia.
Devilliers reported that TWIK-Related K
+
channel TREK-1 -/- mice were more
sensitive than wild-type TREK-1 +/+ mice to painful stimuli, suggesting that
activation of TREK-1 could result in pain inhibition. Various approaches of drug
discovery were explored in order to develop original analgesic drugs targeting
PSD-95 and TREK-1.
Biography
Sylvie Ducki has completed her PhD from the University of
Manchester (UK) and Postdoctoral studies at the Arizona State
University (USA). She joined the University of Salford for a 6-year
lectureship and has been a Professor in Organic and Medicinal
Chemistry at Sigma Clermont (France) for 11 years. She has
published more than 60 papers in reputed journals and has
been serving as an Editorial Board Member of various journals
including Anti-Cancer Agents in Medicinal Chemistry, Current
Chemical Biology, Medicinal Chemistry.
Sylvie.Ducki@Sigma-Clermont.frAddressing the opioid crisis by developing analgesic drugs with
novel modes of action
Sylvie Ducki
Universite Clermont Auvergne, Institut de Chimie de Clermont-Ferrand, Clermont-Ferrand, France
Sylvie Ducki, J Org Inorg Chem 2018, Volume: 4
DOI: 10.21767/2472-1123-C2-005